[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bronchiolitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bronchiolitis":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,46,58,89,115,138,159,188,209,239,277,307,329,355,375,418,443,471,495,517,540,564,587,614,647],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100053455","phase-4-the-lalelalung-study-digital-stethoscope-clinical-evaluation-100053455",false,"NCT07631377","The LalelaLung Study: Digital Stethoscope Clinical Evaluation","LaLeLa","Inclusion Criteria:\n\n* Age 2 to 59 months at the time of screening\n* Presence of cough and\u002For difficulty breathing\n* No WHO-defined emergency\u002Fdanger signs (e.g., grunting, cyanosis, apnea, convulsions, or altered level of consciousness)\n* A legal caregiver is present, able to understand the study information, and willing to provide written informed consent\n* Caregiver is willing and able to provide contact information (e.g., mobile phone number) to allow 7-day follow-up after the clinic visit\n\nExclusion Criteria:\n\n* Presence of WHO-defined emergency signs requiring immediate referral or hospital admission (grunting, cyanosis, apnea, uncompensated shock, convulsions, diarrhea with severe dehydration, or altered level of consciousness)\n* Critical illness or clinical instability judged by the screening clinician or study physician to require urgent medical attention\n* Age outside the target range (younger than 2 months or older than 59 months)\n* Previous enrollment in the study\n* Refusal or withdrawal of informed consent by the legal caregiver at any time prior to randomization","ALL","2 Months","59 Months",{"count":21,"type":22},350,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Pneumonia is the leading infectious cause of death in children under five years of age worldwide, and most of these deaths occur in low- and middle-income countries. In these settings, frontline health workers diagnose pneumonia using the World Health Organization's Integrated Management of Childhood Illness (IMCI) guidelines, which rely mainly on counting how fast a child is breathing and checking for chest indrawing. This approach has saved many lives, but it is not very specific. As a result, many children who actually have self-limiting viral illnesses that do not require antibiotics are nonetheless treated with antibiotics, contributing to the global rise of antimicrobial resistance.\n\nNew digital stethoscopes paired with artificial intelligence (AI) can record a child's lung sounds and automatically detect abnormal sounds such as crackles and wheezes with accuracy comparable to physicians. The LaLeLa Lung Study will evaluate whether adding an AI-enabled digital stethoscope to standard IMCI assessment improves the accuracy of pneumonia diagnosis among children aged 2 to 59 months who present with cough and\u002For difficult breathing at a primary care clinic in Cape Town, South Africa.\n\nThe main component (Objective 1) is a randomized, triple-blinded diagnostic accuracy study that will enroll 350 children, randomly assigned in a 1:1 ratio to either IMCI care enhanced by the AI-enabled digital stethoscope or standard IMCI care. An independent panel of physicians, blinded to the AI results and to study-arm assignment, will review each case and serve as the reference standard for determining whether pneumonia was truly present. The investigators hypothesize that IMCI enhanced by the AI stethoscope will diagnose pneumonia more accurately, and target antibiotics more appropriately, than standard IMCI alone. Nested sub-studies will additionally evaluate a second AI stethoscope for tuberculosis detection, a wearable lung-sound and respiratory-rate patch, an automated respiratory-rate monitor, and a smartphone-connected pulse oximeter.\n\nA separate component (Objective 2) is a mixed-methods implementation study at a second clinic that will assess how easily health workers can use these devices, how acceptable the devices are to health workers and caregivers, and how well the devices fit into routine clinic workflows.\n\nThroughout the study, all AI-generated results will remain concealed from clinic staff, study clinicians, and caregivers, so the AI-generated results will not influence the care any child receives. All children continue to receive standard IMCI care. Findings will help inform whether AI-enabled digital auscultation should be integrated into childhood pneumonia care in South Africa and similar low-resource settings, with the goal of improving diagnosis, strengthening antibiotic stewardship, and reducing antimicrobial resistance and child mortality.",[28,29,30,31,32,33],"Pneumonia","Tuberculosis, Pulmonary","Respiratory Tract Infections","Bronchiolitis","Respiratory Sounds","Antibiotic Resistant Strain","NOT_YET_RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":22},"2026-08-17",{"date":42,"type":22},"2028-06-30",{"name":44,"class":45},"Johns Hopkins University","OTHER",{"id":47,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":49,"briefSummary":26,"conditions":50,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":57,"locationsCount":4},"100643415",{"count":21,"type":22},[25],[28,29,30,31,32,33],"2026-06-05",{"date":53,"type":38},"2026-06-09",{"date":55,"type":22},"2026-07-20",{"date":42,"type":22},{"name":44,"class":45},{"id":59,"slug":60,"hasResults":12,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100587742","evaluation-of-the-impact-of-ehr-alerts-on-clinical-decision-support-pathway-use-in-bronchiolitis-and-the-impact-of-pathway-use-on-the-prescription-of-high-flow-nasal-cannula-and-other-elements-of-high-value-care-100587742","NCT06932341","Evaluation of the Impact of EHR-Alerts on Clinical Decision Support Pathway Use in Bronchiolitis, and the Impact of Pathway Use on the Prescription of High Flow Nasal Cannula and Other Elements of High Value Care.","The Impact of EHR-Alerts on the Use of an EHR-Integrated Clinical Decision Support Pathway and the Use of High Flow Nasal Cannula in Bronchiolitis","Patient Inclusion Criteria:\n\n* Children \\\u003C=24 months of age presenting to the emergency room and\u002For hospitalized (under observation or inpatient status) with EHR-indicators of bronchiolitis at one of three study sites. EHR-indicators of bronchiolitis include the use of bronchiolitis-specific order sets, or specific combinations of ED chief complaint, infection or isolation status, and the receipt of disease-relevant therapies (such as oxygen supplementation)\n\nPatient Exclusion Criteria:\n\n* Current encounter is birth-encounter\n* Currently hospitalized in an ICU\n* Hospitalized with length of stay \\>14 days","24 Months",{"count":67,"type":22},8000,[69],"NA","The goal of this experimental study is to learn whether different types of Electronic Health Record (EHR) alerts that direct clinicians to reference clinical guidelines embedded in the increase the use of these guidelines and the delivery of evidence-based care in children presenting to the hospital with bronchiolitis. The main questions it aims to answer are:\n\n* Do EHR-alerts increase clinicians' us of evidence-based EHR-integrated Clinical Decision Support (CDS) guidelines for the care of bronchiolitis and\n* Is the use of EHR-integrated CDS-guidelines for the care of bronchiolitis associated with deceases in low-value use of High Flow Nasal Cannula (HFNC) and improvement in other aspects of high-value care for this disease\n\nPatients will be randomized on the encounter-level to have the patient's treating providers receive no EHR-alert or one of two types of EHR-alert (non-interruptive or interruptive) reminding the provider that the EHR-integrated CDS guideline is available for the care or bronchiolitis. Researchers will compare the rate of use of EHR-integrated CDS guidelines in patients whose clinicians did not receive any EHR-alerts, to those whose clinicians received a non-interruptive alert and to those whose clinicians received an interruptive Best Practice Advisory (BPA). In addition, the study will evaluate whether the utilization of the EHR-integrated CDS guideline in a given encounter was associated with less low-value HFNC use, and differences in other elements of low-value care for bronchiolitis.\n\nPatients in all groups will continue to receive standard hospital care for bronchiolitis as determined by the patient's treating clinicians.",[31],[73,74,75,76,77,78],"best practice advisory","clinical decision support","clinical guideline","clinical pathway","practice advisory","EHR alert","RECRUITING","2026-05-26",{"date":82,"type":38},"2026-05-29",{"date":84,"type":38},"2025-05-05",{"date":86,"type":22},"2026-07-14",{"name":44,"class":45},3,{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":17,"minAge":95,"maxAge":65,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100588812","phase-3-characterization-of-bronchodilator-response-in-children-with-bronchiolitis-using-phenotypic-and-genotypic-features-100588812","NCT06946264","Characterization of Bronchodilator Response in Children With Bronchiolitis Using Phenotypic and Genotypic Features","Inclusion Criteria:\n\n* Children between 3 to 24 months of age\n* Clinical diagnosis of bronchiolitis by the treating provider(s), defined by the American Academy of Pediatrics as a clinical syndrome involving lower respiratory tract symptoms\n* Children who either have no history of prematurity or have a history of prematurity but without associated co-morbidities\n* Emergency department (ED) visit to seek care at Nemours Children's Health-Florida (NCH-FL)\n\nExclusion Criteria:\n\n* Patients previously enrolled in the PI's K12 study\n* Documented history of asthma or reactive airway disease\n* Co-morbidities affecting airway response (e.g., chronic lung disease, bronchopulmonary dysplasia, bronchiectasis, congenital heart disease, immunodeficiency, neurologic condition)\n* Diagnosis of pneumonia by chest radiography\n* Inhaled, nebulized, or oral corticosteroid use within 72 hours of ED evaluation\n* Inhaled, nebulized, or oral bronchodilator administration within 4 hours of ED arrival","3 Months",{"count":97,"type":22},400,[99],"PHASE3","Bronchiolitis is the leading cause of pediatric morbidity and healthcare costs. Despite the commonplace use of bronchodilator treatments, like albuterol, in conditions like asthma, their efficacy in bronchiolitis remains controversial due to the heterogeneity in patient response. Although studies indicate that bronchodilators do not enhance outcomes in bronchiolitis, meta-analyses can obscure the heterogeneity of treatment effects. While bronchodilator response genetics have not been explored in bronchiolitis, treatment effectiveness variations often depend on genomic factors. Genome-wide association studies (GWAS) have linked genetic variants with bronchodilator response and outcomes in childhood asthma, suggesting a bronchodilator-responsive genotype. This proposal aims to extend this paradigm to bronchiolitis, addressing the gap in knowledge where GWAS and clinical characteristics intersect. The proposed study's objective is to characterize phenotypic and genotypic variations of children with bronchiolitis and their association with bronchodilator response. We hypothesize that children with bronchiolitis who exhibit clinical and historical characteristics associated with atopy and specific physical findings have genetic variants linked to bronchodilator response. To achieve this, we propose to (Aim 1) define airway responsiveness to bronchodilator treatment in children with bronchiolitis using the change in respiratory score, (Aim 2a) identify the associations between candidate genetic variants and bronchodilator response among children with bronchiolitis, and (Aim 2b) determine the associations between candidate genetic variants and clinical patient data to identify bronchodilator-responsive children with bronchiolitis. A prospective, double-blind, randomized, placebo-controlled trial of a single albuterol dose in children aged 3 to 24 months presenting with bronchiolitis to the emergency department will be conducted to achieve these aims. Patient information and respiratory assessment outcomes will be collected before and after intervention. Blood, urine, DNA buccal swabs, and nasopharyngeal swabs will also be collected. Completion of these aims will result in a novel clinical prediction model for bronchodilator response determination in bronchiolitis, integrating clinical, physical, and genetic data. Furthermore, this research supports the candidates' career development goals of advancing training in clinical trial research design and execution and becoming an expert in clinical and translational methods to enhance pediatric emergency department health and outcomes. Ultimately, this work will inform an R01 application to validate an evidence-based prediction rule for identifying bronchodilator-responsive children with bronchiolitis through a multi-center emergency medicine research network, optimizing therapeutic approaches, and reducing resource use in those with a low likelihood of bronchodilator response.",[31,102],"Bronchodilator Agents",[104],"double-blind randomized clinical trial","2026-05-06",{"date":107,"type":38},"2026-05-08",{"date":109,"type":38},"2022-07-08",{"date":111,"type":22},"2030-12-31",{"name":113,"class":45},"Nemours Children's Clinic",1,{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":114},"100580817","descriptive-study-of-the-initial-management-of-young-children-with-moderate-acute-bronchiotitis-with-home-hospitalisation-100580817","NCT06842238","Descriptive Study of the Initial Management of Young Children With Moderate Acute BRONCHiotitis With Home Hospitalisation","BRONCHAD","Inclusion Criteria:\n\n* Any infant with moderate bronchiolitis according to the HAS definition (except for the SpO2 criterion which must be greater than or equal to 92% to avoid the patient being on oxygen therapy upon admission)\n* Age \\> 2 months and ≤ 2 years\n* Respiratory syndrome for 48 hours\n* Infant with a first episode of bronchiolitis\n* Referral of the general practitioner\u002Ftreating pediatrician for home hospitalisation care\n* Parents' agreement for the choice of home hospitalisation care\n* Non-opposition or free and informed consent of both parents to the use of the child's health data\n\nExclusion Criteria:\n\n* Patient not receiving health protection\n* Comorbidities: congenital heart disease with shunt, chronic pulmonary pathology including bronchopulmonary dysplasia, neuromuscular pathology, immune deficiency, multiple disabilities Congenital heart disease\n* Refusal of one or both parents for the proposed pathway\n* Doubts about the parents' understanding of the nature of home hospitalisation care\n* Severe bronchiolitis or with saturation \\\u003C 92%\n\n  * Moderate bronchiolitis but evolving for less than 48 hours\n  * Cases of psychiatric pathologies or depressive syndrome diagnosed in the parents.","2 Years",{"count":124,"type":22},40,"OBSERVATIONAL","The occurrence of a first episode of acute bronchiolitis in an infant or young child (3 months-2 years) always represents a medical event that generates stress for parents and in some cases for the primary care physician when it is necessary to decide on the child's orientation for treatment. Each year, during the winter season, this pathology affects 30% of infants under two years old (480,000 annual cases in France), generates approximately 30,000 hospitalizations and exposes to an overall mortality risk of 0.08%.\n\nAccording to the recommendations of the HAS (2019), moderate bronchiolitis does not require systematic hospitalization and can be managed in a Home Hospitalization (HAD) context.\n\nWhen the child's examination data do not find signs of severity, the SpO2 measurement is greater than 92% and the family context allows for return home, HAD management is a reasonable option and represents an alternative to the classic scheme of assessing the level of severity by the emergency department and subsequent hospitalization if necessary. HAD management is carried out within the framework of a very structured \"patient pathway\", codified and supervised by the pediatric teams and doctors of this department. This patient pathway concerns children with a moderate form of bronchiolitis without oxygen requirements at the time of inclusion. This must be 48 hours from the onset of the child's respiratory clinical signs.\n\nThe main objective of this study is to describe the need for oxygen therapy for a young child with moderate acute bronchiolitis syndrome during home hospitalization (HAD) care.",[31,128],"Bronchiolitis Acute","2026-04-20",{"date":131,"type":38},"2026-04-21",{"date":133,"type":38},"2025-06-14",{"date":135,"type":22},"2027-03-14",{"name":137,"class":45},"Elsan",{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":17,"minAge":144,"maxAge":4,"enrollmentInfo":145,"targetDuration":147,"studyType":125,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":114},"100288468","deployment-related-lung-disease-research-database-and-biorepository-100288468","NCT03035097","Deployment-Related Lung Disease Research Database and Biorepository","Inclusion Criteria:\n\n* Served in the southwest Asia wars\n\nExclusion Criteria:\n\n* Did not served in the southwest Asia wars","18 Years",{"count":146,"type":22},500,"1 Day","The purpose of this research study is to establish a research database and biorepository for patients at National Jewish Health (NJH) who served in Operation Iraqi Freedom (OIF) or Operation Enduring Freedom (OEF). This study will also include civilian contractors who worked as part of these military operations in Iraq or Afghanistan. The biorepository would store blood samples obtained from these patients during a clinic visit. The research database would store prospectively and retrospectively collected clinical and exposure data that would enable us to comprehensively characterize each case.",[31],"2026-04-10",{"date":152,"type":38},"2026-04-15",{"date":154,"type":4},"2013-02",{"date":156,"type":22},"2030-12",{"name":158,"class":45},"National Jewish Health",{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":17,"minAge":166,"maxAge":65,"enrollmentInfo":167,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100631802","risk-factors-and-severity-of-bronchiolitis-in-hospitalized-children-at-assiut-university-hospital-100631802","NCT07505420","Risk Factors and Severity of Bronchiolitis in Hospitalized Children at Assiut University Hospital","Clinical Epidemiology, Risk Factors Associated With Severity and Disease Burden of Bronchiolitis in Hospitalized Children in Assiut University Hospital","Inclusion Criteria:\n\n* Children aged 1-24 months presenting with acute bronchiolitis, defined per AAP 2014 criteria: preceding upper respiratory infection, wheezing, tachypnoea (\\>60 breaths\u002Fmin \\\u003C2 months, \\>50 \\\u003C12 months, \\>40 \\>12 months), and signs of respiratory distress (nasal flaring, grunting, retractions).\n* Confirmed clinical diagnosis by a pediatric pulmonologist.\n\nExclusion Criteria:\n\n* Known congenital heart disease, chronic lung disease (e.g., bronchopulmonary dysplasia), immunodeficiency, or neuromuscular disorders.\n* Recurrent wheezing suggesting asthma.\n* Gestational age \\\u003C32 weeks without recovery or birth weight \\\u003C1500g without catch-up growth.\n* Immunosuppression, recent (within 2 weeks) systemic steroids or antibiotics.","1 Month",{"count":168,"type":22},65,"The purpose of this observational study is to identify the risk factors that make bronchiolitis more severe in infants and toddlers. Bronchiolitis is a common viral lung infection that causes inflammation and airway obstruction, often leading to breathing difficulties and hospitalization in young children.\n\nResearchers will observe approximately 65 children, aged 1 to 24 months, who are admitted to Assiut University Hospital for acute bronchiolitis. Because this is an observational study, participants will receive standard medical care, and no experimental treatments will be tested.\n\nDuring the hospital stay, researchers will collect information through parent questionnaires and standard medical records. The research team will gather data on:\n\n* Family, social, and environmental factors, such as infant feeding practices, premature birth, and exposure to passive smoking.\n* The child's clinical symptoms and overall severity of illness upon arrival at the hospital.\n* Routine test results and the types of supportive care the child needs, such as extra oxygen or feeding assistance.\n* The total length of the hospital stay and whether the child requires intensive care (ICU) admission.\n\nBy identifying which factors are most closely linked to severe illness, the study aims to help doctors better predict the course of the disease early on, evaluate adherence to treatment guidelines, and ultimately reduce the health burden of bronchiolitis.",[31,171,172],"Acute Bronchiolitis","Respiratory Syncytial Virus Infection",[31,171,174,175,30,176,177,178],"Respiratory Syncytial Virus Infections","Lower Respiratory Tract Infection","Viral Respiratory Infection","Wheezing","Respiratory Distress","2026-03-26",{"date":181,"type":38},"2026-04-01",{"date":183,"type":22},"2026-05",{"date":185,"type":22},"2027-06",{"name":187,"class":45},"Assiut University",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":17,"minAge":147,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":114},"100630302","national-observatory-of-children-hospitalized-with-bronchiolitis-100630302","NCT07485907","National Observatory of Children Hospitalized With Bronchiolitis","OVNI3","Inclusion Criteria:\n\n* Children under 12 months\n* Treated at one of the 12 study sites\n* From October 15, 2025 to February 15, 2026\n* For acute bronchiolitis defined according to current national and international recommendations\n* Hospitalized\n\nand\n\n* RSV testing\n* Known nirsevimab immunization status for the ongoing 2025\u002F2026 season\n\nExclusion Criteria:\n\n* Refusal to participate by the legal representative\n* Maternal immunization with abrysvo after September 1st 2025","12 Months",{"count":197,"type":22},1000,"OVNI3 is multicenter, non-interventional study based on the analysis of retrospective patient data extracted from medical records and collected as part of routine clinical care following hospitalization for bronchiolitis",[31],"2026-03-17",{"date":202,"type":38},"2026-03-20",{"date":204,"type":22},"2026-03-15",{"date":206,"type":22},"2027-03-15",{"name":208,"class":45},"Association Clinique Thérapeutique Infantile du val de Marne",{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":17,"minAge":166,"maxAge":65,"enrollmentInfo":217,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":235,"leadSponsor":237,"locationsCount":114},"100625055","gut-microbiome-and-immune-response-in-severe-rsv-infection-in-vietnamese-infants-100625055","NCT07417657","Gut Microbiome and Immune Response in Severe RSV Infection in Vietnamese Infants","Impact of the Gut Microbiome on Immune Response and Disease Severity in Acute Respiratory Syncytial Virus (RSV) Infection in Vietnamese Children: A Prospective Observational Study","GUT-LUNG RSV","Inclusion Criteria:\n\nAge 1 to 24 months RT-PCR positive for RSV from respiratory specimen Symptoms consistent with acute lower respiratory tract infection Parent\u002Flegal guardian provides informed consent\n\nExclusion Criteria:\n\nPrematurity \\\u003C32 weeks gestation or birthweight \\\u003C1500 g Chronic conditions (e.g., congenital heart disease, chronic lung disease, chronic liver\u002Fkidney disease) Primary or acquired immunodeficiency Severe malnutrition (weight-for-age Z-score \\\u003C -3 SD) Antibiotic use within 2 weeks before admission Probiotic use within 4 weeks before admission Co-infection with other pathogens (viral\u002Fbacterial) Stool sample not obtained within 24 hours of admission",{"count":218,"type":22},250,"Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection in young children, and a substantial proportion of severe cases occur in previously healthy infants. The gut-lung axis suggests that gut microbiome composition may modulate respiratory immune responses. This prospective observational study in Vietnam will compare gut microbiome profiles and systemic immune cytokine responses between infants with severe RSV infection and those with mild RSV infection, aiming to identify microbiome-immune signatures associated with disease severity.",[172,31,221],"Viral Lower Respiratory Tract Infection (LRTI)",[223,224,225,226,227,228,229,31,230],"RSV","gut microbiome","16S rRNA","Gut-lung axis","Vietnam","infants","Biomarkers","Lower respiratory tract infection","2026-02-11",{"date":233,"type":38},"2026-02-18",{"date":181,"type":22},{"date":236,"type":22},"2029-12-31",{"name":238,"class":45},"Phuc Huu Phan",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":250,"conditions":251,"keywords":256,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":276},"100624563","premabiom-metatranscriptomics-of-the-respiratory-microbiome-to-predict-the-occurrence-of-bronchopulmonary-dysplasia-in-preterm-infants-100624563","NCT07411261","PremaBiom: Metatranscriptomics of the Respiratory Microbiome to Predict the Occurrence of Bronchopulmonary Dysplasia in Preterm Infants","PremaBiom","Inclusion Criteria:\n\n* Preterm infants with gestational age at birth lower than 32 gestational weeks and 6 days.\n* Hospital stay in one of the participant neonatal care units\n* Infants covered by the social security system of at least one of their parents\n* Whose parents have been informed about the study and agree to sign the informed consent form\n\nExclusion Criteria:\n\n* Palliative care only\n* Lack of parental consent\n* Parents who are minors or under legal protection (guardianship, conservatorship, judicial protection)\n* Parents who do not speak French","72 Hours",{"count":248,"type":22},270,[69],"The goal of this clinical trial is to understand the impact of respiratory microbiome maturation in respiratory health of preterm infants under 32 gestational weeks. The main questions it aims to answer are:\n\n* What is the role of microbiome maturation in respiratory health (development of bronchopulmonary dysplasia, childhood asthma and viral respiratory infections) of preterm infants ?\n* Which environmental or health factors are involved in the maturation of the respiratory microbiome ?\n\nParticipants will undergo follow-up from birth until 3 years of corrected age including nasal swabs, stool samples, and for some of them blood and milk sample.",[252,253,254,31,255],"Bronchopulmonary Dysplasia","Preterm Infant Development","Asthma Childhood","Viral Respiratory Tract Infections",[257,258,259,260,261,262,263,264,265,266,267],"respiratory microbiome","bronchopulmonary dysplasia","Prematurity","asthma","bronchiolitis","inflammation","inate immunity","respiratory tract infections","dysbiosis","personalized medicine","metatranscriptomics",{"date":269,"type":38},"2026-02-13",{"date":271,"type":22},"2026-03",{"date":273,"type":22},"2031-03",{"name":275,"class":45},"University Hospital, Caen",6,{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":17,"minAge":285,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":288,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":306},"100613120","assessement-of-effectiveness-of-seawater-nasal-sprays-on-sinonasal-symptoms-100613120","NCT07262450","Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms","Real-word Study to Assess Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms","SeaBridge","Inclusion criteria:\n\n* Subject's age and medical condition in compliance with the intended use and population\n* Subjects who, from the investigator's judgement, should benefit from nasal wash in accordance with routine medical practice\n* Subjects with at least two nasal symptoms of intensity ≥ 3 (6 modalities intensity SNOT-22 rating-scale) among the following:\n\n  * Nasal blockage\u002Fnasal congestion\u002F stuffy nose;\n  * Runny nose;\n  * Need to blow\u002Fclear the nose;\n  * Sneezing;\n  * Thick nasal discharge\u002Fsecretions;\n  * Decreased sense of smell \u002Ftaste (replaced by \"noisy breathing\u002Fmouth breathing\" for infants)\n* Subjects with impaired nasal breathing (score ≥ 3, 6-modalities intensity rating-scale), induced by the presence of nasal symptoms\n* For acute indications (only): subjects with symptoms started not later than 72 hours prior to enrolment (Day 0).\n* For allergic rhinitis indication: perennial allergic rhinitis with and without seasonal allergic rhinitis\n* For post-surgery indication: septoplasty and rhinoseptoplasty.\n* Subject\u002Fparent willing to perform nasal wash following advices received from HCPs.\n* Subjects (or parents for babies and children) agreeing to follow the study requirements during the whole study period (up to 3 months).\n* Subject (or parent for baby and children) able to understand verbal and written local language and in capacity to fill-in questionnaire by himself.\n* Subject having daily access to internet to answer online questionnaire.\n* Subject or Parent\u002Flegal guardian of the subject has given freely and expressly her\u002Fhis informed consent.\n* Subject affiliated to the health social security system or beneficiary of an equivalent system\n\nNon-inclusion criteria:\n\n* Subject with contraindications according to each IFU.\n* Hypersensitivity or known allergy to any component of the investigational products.\n* Subject taking part in another clinical study or being in the exclusion period of another clinical study.\n* Subject already using nasal wash to manage his nasal symptoms.\n* Subject already included once in the study.\n* Subject with a member of his household already included in the study if still in the follow-up phase.\n* Subject deprived of liberty by administrative or judicial decision or under legal guardianship.","15 Days",{"count":287,"type":22},1065,[69],"The purpose of this post-market clinical investigation is to assess in a real-life setting, the effectiveness, usage, tolerance, safety and satisfaction of 4 isotonic and hypertonic seawater-based CE-marked nasal sprays.\n\nThe main questions it aims to answer are:\n\n* Efficacy,\n* Safety,\n* Usage,\n* Satisfaction, in real-life usage among infants, children, adults and pregnant or breastfeeding women suffering from acute and chronic sinonasal pathologies. The 4 medical devices under investigation will be used in accordance with their intended use, target populations and medical indications.",[291,31,292,293,294,295],"URTI","COVID - 19","Allergic Rhinitis","Chronic Rhinosinusitis (CRS)","Post-surgery","2025-12-01",{"date":298,"type":38},"2025-12-03",{"date":300,"type":38},"2025-08-27",{"date":302,"type":22},"2026-08",{"name":304,"class":305},"Laboratoire de la Mer","INDUSTRY",32,{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":17,"minAge":314,"maxAge":122,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":114},"100520216","non-invasive-ventilation-versus-neurally-adjusted-ventilatory-assistance-nava-for-the-treatment-of-bronchiolitis-100520216","NCT06053684","Non-Invasive Ventilation Versus Neurally-Adjusted Ventilatory Assistance (NAVA) for the Treatment of Bronchiolitis","Comparison of Conventional Non-Invasive Ventilation and Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Ventilation for the Treatment of Bronchiolitis","Inclusion Criteria:\n\n* Patients under the age of two years old with a diagnosis of bronchiolitis presenting to the pediatric ICU\n* Patient's provider believes there is equipoise between the use of NAVA or conventional non-invasive ventilation for the patient\n\nExclusion Criteria:\n\n* Patients unable to utilize a nasogastric tube\n* Patients with a diagnosis of chronic lung disease, cyanotic heart lesions, or congestive heart failure\n* Patients with hypotonia\n* Patients likely to require imminent intubation: \\>0.60 Fraction of Inspired Oxygen (FiO2); Carbon Dioxide (CO2) \\> 60, frequent apneas, clinician determines patient unlikely to tolerate non-invasive modality)\n* Patients with hemodynamic instability, defined as the need for vasoactive medication","0 Years",{"count":316,"type":22},130,[69],"This project aims to answer whether the use of a Neurally-Adjusted Ventilatory Assistance mode for non-invasive ventilation in pediatric patients with bronchiolitis results in improved comfort and reduced escalations in therapy (including intubation) when compared to using a standard mode of non-invasive ventilation. Neurally-Adjusted Ventilatory Assistance (NAVA) has been shown to result in greater synchrony then the standard mode of non-invasive ventilation. The study team hypothesizes that this improved synchrony can result in important clinical improvements when NAVA is used to treat children with bronchiolitis.",[31],"2025-08-28",{"date":322,"type":38},"2025-09-05",{"date":324,"type":38},"2023-12-18",{"date":326,"type":22},"2027-03",{"name":328,"class":45},"Montefiore Medical Center",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":337,"maxAge":195,"enrollmentInfo":338,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":352,"locationsCount":354},"100555006","low-value-care-and-variation-in-practice-for-children-hospitalized-with-bronchiolitis-100555006","NCT06506474","Low-value Care, and Variation in Practice for Children Hospitalized With Bronchiolitis","Low-value Care, and Variation in Practice for Children Hospitalized With Bronchiolitis - a Multicentric Prospective Observational Study","CareBEST","Inclusion Criteria:\n\n* Children aged \\>28 days to \\\u003C12 months\n* Children admitted to a pediatric inpatient ward with an admission diagnosis of bronchiolitis\n\nExclusion Criteria:\n\n\\- Children previously recruited for the study, either during a previous bronchiolitis admission or for the same incident of bronchiolitis, while admitted to another study site.","28 Days",{"count":339,"type":22},3000,"Low-value care is defined as the use of a health service, such as diagnostics and treatments, for which the harms or costs outweigh the benefits. In pediatrics, investigations or treatments can be unpleasant or traumatizing to the child, can prolong the time spent in hospital, and can create a cascade of further futile investigations and treatments. Several of the commonly used diagnostics and treatments in bronchiolitis are considered low-value, making it a great model to study low-value care in pediatrics.\n\nThe purpose of CareBEST is to study the use of 6 low-value healthcare services in children aged 1 to 12 months hospitalized with bronchiolitis, their costs, and measure the variability in practice of these services.\n\nThe main questions this study aims to answer are:\n\n1. How frequently are 6 low-value care health services used in children hospitalized with bronchiolitis? These 6 low-value care health services are: 1) respiratory virus testing; 2) chest x-rays; 3) continuous pulse oximetry; 4) short-acting beta-agonists; 5) systemic corticosteroids; and 6) antibiotics.\n\n   * Are there factors that predict the use of these services?\n   * What are the costs of the use of these services?\n2. How much variability is there between different patients, different doctors, and between hospitals in the use of these 6 low-value health services ?\n3. Are differences in use of low-value health services associated with patient and family characteristics (like race and ethnicity, socioeconomic status, language), and do these contribute to disparities in care?\n\nParticipants will have their infant's medical chart reviewed during their hospitalization. They will also have 2 short questionnaires to complete, once during their child's admission to the hospital, and one 30 days later to ask about whether their child required any additional medical care. They will additionally be asked to complete a questionnaire on their perceptions regarding their child's care while hospitalized, including the use of shared-decision making and their understanding of and involvement in the care decisions made.\n\nThis analysis will provide a better understanding of treatment of bronchiolitis in Canada and help in the development of effective interventions to reduce low-value care.",[31],[228,343,261,344,345],"hospitalization","low-value care","observational study","2025-07-18",{"date":348,"type":38},"2025-07-23",{"date":350,"type":38},"2024-02-13",{"date":185,"type":22},{"name":353,"class":45},"St. Justine's Hospital",15,{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":122,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":373,"locationsCount":114},"100509141","respiratory-support-and-treatment-for-efficient-and-cost-effective-care-100509141","NCT05909566","Respiratory Support and Treatment for Efficient and Cost-Effective Care","REST EEC","Inclusion Criteria:\n\n* \\\u003C2 years of age Bronchiolitis WOB Score \\>2\n\nExclusion Criteria:\n\n* Immunocompromised\n* Immunosuppressed\n* Chronic lung disease\n* Congenital heart disease with baseline cardiorespiratory manifestations",{"count":363,"type":22},198,[69],"This project aims to answer the essential questions about the management of acute, pediatric respiratory illness, accelerate recovery from these all-too-common diseases, curb unnecessary costs of care, and demonstrate UPMC Children's Hospital of Pittsburgh's capabilities as the premier, world-class leader in the arena of pediatric learning healthcare systems. REST EEC will focus on the question of whether clinical decision support (CDS) facilitates the standardization of the initiation and weaning of heated high flow nasal cannula (HHFNC) for bronchiolitis.REST EEC will focus on whether the application of CDS improves adherence to a standardized guideline and leads to improved patient-centered outcomes.",[31],"2025-07-07",{"date":369,"type":38},"2025-07-11",{"date":371,"type":38},"2023-10-25",{"date":183,"type":22},{"name":374,"class":45},"Christopher Horvat",{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":384,"conditions":385,"keywords":389,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":114},"100594116","assessing-the-burden-of-respiratory-syncytial-virus-rsv-100594116","NCT07015255","Assessing the Burden of Respiratory Syncytial Virus (RSV)","Assessing the Burden of Respiratory Syncytial Virus (RSV): the Assessment of the Burden of Respiratory Syncytial Virus (RSV) Across Different Age Groups and Risk Factors","Inclusion Criteria:\n\n* Patients of all ages with a confirmed diagnosis of RSV infection\n* Patients admitted to a SEHA hospital or healthcare facility between January 2018 and December 2024\n* Patients with documented data in the SEHA electronic medical record (EMR) system\n\nExclusion Criteria:\n\n* Patients with suspected RSV infection that is not laboratory-confirmed\n* Patients without sufficient data in the SEHA EMR system",{"count":383,"type":22},1500,"This study examines the impact of Respiratory Syncytial Virus (RSV) on people of all ages, from infants to the elderly. It uses hospital records collected between January 2018 and December 2024 to understand:\n\n* How often does RSV occur\n* Who is most at risk\n* The long-term and financial effects of RSV",[386,387,31,28,388],"Respiratory Syncytial Virus (RSV) Infection","Acute Lower Respiratory Tract Infections","Chronic Respiratory Conditions",[390,223,391,392,393,394,395,396,397,398,399,400,401,402,403,404,31,28,405,406,407],"Respiratory Syncytial Virus","RSV Infection","RSV in Infants","RSV in Adults","RSV Hospitalization","RSV Epidemiology","RSV Burden","RSV Risk Factors","Retrospective Study","Observational Study","ICU Admissions","RSV Mortality","RSV Cost Analysis","RSV Complications","Asthma and RSV","Recurrent Wheezing","RSV Surveillance","RSV-Related Comorbidities","2025-06-17",{"date":410,"type":38},"2025-06-19",{"date":412,"type":22},"2025-06",{"date":414,"type":22},"2026-06",{"name":416,"class":417},"Abu Dhabi Health Services Company","OTHER_GOV",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":425,"sex":17,"minAge":426,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":114},"100571627","study-of-pneumococcal-carriage-in-rsv-bronchiolitis-in-infants-aged-6-to-18-months-100571627","NCT06722716","Study of Pneumococcal Carriage in RSV Bronchiolitis in Infants Aged 6 to 18 Months","Synergy","Inclusion Criteria:\n\n* Infants aged 6 months to 18 months inclusive\n* With bronchiolitis during RSV epidemic season (bronchiolitis group) or without evidence of RSV viral infection (healthy group)\n* No chronic illness\n* No history of bronchiolitis\n* Signed consent from parents or legal guardians\n* Patient affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Chronic respiratory illness\n* Medical history of bronchiolitis or newborn asthma\n* Treatment with immunosuppressants\n* Patient on AME",true,"6 Months","18 Months",{"count":429,"type":22},120,"The relationship between RSV (human respiratory syncytial virus) infections and invasive infections or pneumonia caused by Streptococcus pneumoniae has been observed epidemiologically for several years. Few fundamental data exist to support the epidemiological relationship. This study will investigate the proportion of pneumococcal carriage in RSV-infected infants and noninfected infants (proportion, serotype profile).",[31],[31,433],"pneumonia","2025-05-12",{"date":436,"type":38},"2025-05-15",{"date":438,"type":22},"2025-10",{"date":440,"type":22},"2026-02",{"name":442,"class":45},"Assistance Publique - Hôpitaux de Paris",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":450,"enrollmentInfo":451,"targetDuration":4,"studyType":23,"phases":452,"briefSummary":453,"conditions":454,"keywords":455,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":470},"100524432","phase-4-efficacy-of-lavender-essential-oil-chest-wraps-in-infants-with-bronchiolitis-100524432","NCT06108648","Efficacy of Lavender Essential Oil Chest Wraps in Infants With Bronchiolitis","Efficacy of Lavender Essential Oil Chest Wraps in Improving Cough and Respiratory Distress in Infants With Bronchiolitis: a Multicenter Randomized Controlled Trial","Inclusion criteria:\n\n* Bronchiolitis: clinical diagnosis based on the combination of respiratory distress (tachypnea, grunting, nasal flaring, retractions, and\u002For need for supplementary oxygen) and fine crackles sometimes accompanied by wheezing on auscultation.\n* Hospitalization.\n* Written informed consent.\n\nExclusion criteria:\n\n* Patients with underlying diseases that impact respiratory or heart function (congenital heart disease, congenital malformation of the lung or airway system and severe chronic lung disease).\n* More than 3 episodes of bronchiolitis.\n* Critically ill infants who have an immediate need for intensive care unit (ICU) admission.\n* Respiratory deterioration needing Continuous positive airway pressure (CPAP) or transfer to ICU during study enrollment.\n* Atopic dermatitis, eczema or other skin lesions (particularly on the chest).\n* Oncologic disease.\n* Premature infants with mild bronchopulmonary dysplasia will not be excluded.","11 Months",{"count":97,"type":22},[25],"The goal of this clinical trial is to learn if lavender essential oil chest wraps relieve cough in infants with bronchiolitis compared to standard care. Furthermore, the researchers will evaluate if breathing difficulties, nighttime awakening and impact on parents will be improved by the lavender oil chest wraps. Infants will be randomized to receive standard care with the addition of lavender oil chest wraps or to receive standard care alone. The study will take place in two locations in Switzerland, at the Geneva University Hospital and the Fribourg Cantonal Hospital.",[31],[261,456,457,458,459,460],"infant","cough","essential oil","lavendula","complementary therapies","2025-03-25",{"date":463,"type":38},"2025-03-30",{"date":465,"type":38},"2023-12-07",{"date":467,"type":22},"2026-04-30",{"name":469,"class":45},"University Hospital, Geneva",2,{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":17,"minAge":166,"maxAge":478,"enrollmentInfo":479,"targetDuration":4,"studyType":23,"phases":480,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":114},"100582406","effect-of-chest-physiotherapy-on-clinical-outcome-of-infants-with-bronchiolitis-100582406","NCT06862895","Effect of Chest Physiotherapy on Clinical Outcome of Infants With Bronchiolitis","Effect of Chest Physiotherapy Educational Program on Mother's Knowledge, Practice and Clinical Outcomes of Infants With Bronchiolitis","Inclusion Criteria:\n\n* 1\\. Mothers of infants diagnosed with bronchiolitis. 2. Presence of crackle on auscultation.\n\nExclusion Criteria:\n\n1. Children with contraindication of chest physiotherapy (ex. Fracture, recent surgery)\n2. Children who intubated and admitted to Intensive Care Unit (ICU).","1 Year",{"count":124,"type":22},[69],"The goal of clinical trial study is to evaluate effect of chest physiotherapy educational on mother's knowledge, practice and clinical outcomes of infants aged less than 12 months diagnosed with bronchiolitis by physician\n\nThe main questions aims to answer:\n\n* Does chest physiotherapy improve clinical outcomes of infants with bronchiolitis?\n* Does educational program improve mothers knowledge and practice regarding chest physiotherapy?\n\nResearcher compare two groups one receive routine hospital care (control group) other receive chest physiotherapy applied by mothers in addition to routine hospital care and will be followed up for 3 days",[31,483,484,485],"Infant, Newborn, Diseases","Chest Physiotherapy","Educational Program","2025-03-03",{"date":488,"type":38},"2025-03-06",{"date":490,"type":38},"2025-01-01",{"date":492,"type":22},"2025-09-01",{"name":494,"class":45},"Hawler Medical University",{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":17,"minAge":147,"maxAge":195,"enrollmentInfo":502,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":503,"conditions":504,"keywords":505,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":88},"100528477","association-of-dysbiosis-and-immune-response-in-bronchiolitis-in-under-12-months--old-infants-100528477","NCT06161285","Association of Dysbiosis and Immune Response in Bronchiolitis in Under 12 Months -Old Infants","BRONCHOBIOTE","Inclusion Criteria:\n\n* Infants \\\u003C12 months\n* With bronchiolitis during RSV epidemic season\n* No chronic illness\n* No bronchiolitis medical history\n* Signed consent from parents or legal guardians\n\nExclusion Criteria:\n\n* Chronic respiratory illness\n* Medical history of bronchiolitis or newborn asthma\n* Treatment with immunosuppressants\n* Patient with no social security affiliation",{"count":429,"type":22},"Acute bronchiolitis is a common disease in children under the age of two, caused mainly by the respiratory syncytial virus (RSV). Furthermore, given the same medical history, it is still very difficult to predict the course and severity of the infection at the onset of symptoms, Some studies have highlighted the importance of the microbiota (intestinal, oral or nasopharyngeal) and of the immune response to RSV in children, We will include 80 children under 2 years old with hospitalized bronchiolitis and non-hospitalized bronchiolitis. Oral, nasal and stool samples will be taken to study the various microbiota in search of dysbiosis. A capillary blood sample will be taken for immune studies.",[31],[506,507,508],"Newborns","Dysbiosis","respiratory syncytial virus (RSV)","2025-02-24",{"date":511,"type":38},"2025-02-26",{"date":513,"type":38},"2024-12-06",{"date":515,"type":22},"2026-04",{"name":442,"class":45},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":426,"maxAge":122,"enrollmentInfo":524,"targetDuration":4,"studyType":23,"phases":526,"briefSummary":527,"conditions":528,"keywords":529,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":538,"locationsCount":88},"100579665","peginterferon--2b-injection-for-the-treatment-of-pediatric-rsv-bronchiolitis-100579665","NCT06827249","Peginterferon α-2b Injection for the Treatment of Pediatric RSV Bronchiolitis","A Multicenter, Randomized, Positive-controlled, Non-inferiority Clinical Study to Evaluate the Safety and Efficacy of Peginterferon α2b Injection in the Treatment of Pediatric RSV Bronchiolitis","Inclusion Criteria:\n\n1. The guardian of the child is able to understand the content, requirements, and limitations of the protocol, fully understands the possible adverse reactions that may occur during the study, is willing to complete the follow-up as required, and voluntarily signs the informed consent form before the start of the study.\n2. The child's age is 6 months or older but no more than 2 years old (including the critical value) at the time of signing the informed consent, and the gender is not specified.\n3. Positive viral detection in nasopharyngeal swab.\n4. Presence of rapid breathing, wheezing, moist rales and\u002For wheezing sounds in the lungs; with or without chest imaging showing signs of hyperinflation, patchy infiltrates, localized atelectasis, and peribronchitis.\n5. The severity of the illness is mild or moderate (evaluation criteria see Appendix 1: Wang Bronchiolitis Scoring Standard).\n6. The time from the onset of the child's illness to the signing of the informed consent form is within 72 hours (the appearance of symptoms and signs related to RSV bronchiolitis does not exceed 72 hours from the signing of the informed consent, including but not limited to: tachypnea, wheezing, hypoxemia, dyspnea, fever).\n7. No use of other antiviral drugs or immunomodulators within 3 weeks before randomization.\n\nExclusion Criteria:\n\n1. Extreme restlessness, drowsiness, coma, and possibly requiring mechanical ventilation assistance for breathing.\n2. Presence of other chronic severe diseases such as cardiac insufficiency, respiratory insufficiency, liver insufficiency, renal insufficiency, and severe malnutrition.\n3. Having autoimmune diseases such as systemic lupus erythematosus or psoriasis, or immunodeficiency diseases.\n4. Having epilepsy or other disorders of central nervous system function.\n5. The investigator's comprehensive judgment suspects a concurrent bacterial infection.\n6. Clinical diagnosis of myocarditis or suspected myocarditis (diagnostic criteria see Appendix 2: Diagnostic Recommendations for Myocarditis in Children).\n7. Known or suspected allergy to interferon or excipients.\n8. Participation in other interventional clinical trials within 3 months prior to screening, or planning to participate in other clinical trials during the study period. (9) A history of pneumonia in the past 3 months.\n\n(10) Other conditions deemed unsuitable for inclusion by the investigator.",{"count":525,"type":22},90,[69],"This is a multicenter, randomized, positive-controlled, non-inferiority clinical study, planning to enroll 90 children with bronchiolitis caused by respiratory syncytial virus infection, to evaluate the safety and efficacy of inhaled Peginterferon α-2b injection compared to recombinant human interferon α2b in the treatment of pediatric respiratory syncytial virus bronchiolitis.",[31],[31,530,531],"Peginterferon α-2b","respiratory syncytial virus","2025-02-09",{"date":534,"type":38},"2025-02-14",{"date":536,"type":22},"2025-03",{"date":185,"type":22},{"name":539,"class":45},"Children's Hospital of Soochow University",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":547,"maxAge":65,"enrollmentInfo":548,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":550,"conditions":551,"keywords":552,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":562,"locationsCount":114},"100572737","utility-of-severity-scales-in-clinical-practice-in-children-hospitalized-due-to-bronchiolitis-100572737","NCT06737159","Utility of Severity Scales in Clinical Practice in Children Hospitalized Due to Bronchiolitis.","Utility of Severity Scales in Clinical Practice in Children Hospitalized Due to Bronchiolitis: Prospective Multicentre Cohort Study.","Inclusion Criteria:\n\nChildren eligible for the trial must fulfil all of the following criteria:\n\n1\\. Children admitted to the hospital with the clinical diagnosis of acute bronchiolitis, which is defined as an apparent viral respiratory tract infection associated with airway obstruction manifested by at least one of following symptoms:\n\n* Tachypnoea (WHO definition).\n* Increased respiratory effort manifested as follows:\n\n  1. Nasal flaring;\n  2. Grunting;\n  3. Use of accessory muscles;\n  4. Intercostal and\u002For subcostal chest wall retractions;\n  5. Apnoe.\n* Crackles and\u002For wheezing. 2. Aged 5 weeks - 24 months old.\n\nExclusion Criteria:\n\n1\\. Diagnosis or suspicion of asthma.","5 Weeks",{"count":549,"type":22},150,"Prospective observational study of patients hospitalized with bronchiolitis. The objective of our study is to compare the accuracy of commonly used clinical scales for bronchiolitis to predict relevant outcomes.",[31],[261,553,554,555],"bronchiolitis severity scoring","validation","utility","2024-12-11",{"date":558,"type":38},"2024-12-17",{"date":560,"type":22},"2024-12",{"date":271,"type":22},{"name":563,"class":45},"Szpital im. Św. Jadwigi Śląskiej",{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":65,"enrollmentInfo":571,"targetDuration":4,"studyType":23,"phases":573,"briefSummary":574,"conditions":575,"keywords":577,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":4},"100567247","comparison-of-3-hypertonic-saline-and-salbutamol-in-children-with-bronchiolitis-100567247","NCT06665711","Comparison of 3% Hypertonic Saline and Salbutamol in Children With Bronchiolitis","COMPARISON BETWEEN 3% HYPERTONIC SALINE VERSUS SALBUTAMOL IN CHILDREN WITH BRONCHIOLITIS","Inclusion Criteria:\n\n* Infants aged 2-24 months\n* Gender; Both Male and female patients.\n* Presenting with bronchiolitis (as per operational definition)\n\nExclusion Criteria:\n\nInfant with metabolic disorder\n\n* Congenital heart disease\n* Immune deficiency",{"count":572,"type":22},100,[69],"Bronchiolitis is a common lower respiratory tract infection that often leads to hospitalization in infants. The use of nebulized 3% hypertonic saline for treating bronchiolitis is being explored as an alternative to Salbutamol. In nebulizers, normal saline serves as a diluent, allowing water molecules or drugs to be inhaled into the lungs. However, there has been limited research on this topic, and no local trials have been conducted.\n\nThis study aims to compare the effectiveness of 3% hypertonic saline and Salbutamol in treating bronchiolitis. A randomized controlled trial will be conducted at the Department of Pediatric Medicine, Services Institute of Medical Sciences, Lahore, over one year, involving 100 infants divided into two groups: one receiving 3% hypertonic saline and the other receiving Salbutamol. The RDAI score will be evaluated before and during treatment to assess recovery time. Data will be collected using a proforma and analyzed with SPSS v25. The study aims to determine which treatment leads to faster symptom control and shorter hospital stays, with significance defined as a p-value ≤0.05. The findings will guide future treatment choices for infants with bronchiolitis.",[576],"BRONCHIOLITIS",[576],"2024-10-29",{"date":580,"type":38},"2024-10-30",{"date":582,"type":22},"2024-12-03",{"date":584,"type":22},"2025-03-10",{"name":586,"class":45},"University of Health Sciences Lahore",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":17,"minAge":195,"maxAge":595,"enrollmentInfo":596,"targetDuration":4,"studyType":23,"phases":598,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":470},"100564507","artificial-intelligence-based-voice-assessment-of-children-and-adults-respiratory-conditions-100564507","NCT06630078","Artificial Intelligence-based Voice Assessment of Children and Adults Respiratory Conditions","Artificial Intelligence-based Voice Assessment of Children and Adults With Acute and Chronic Respiratory Conditions: Diagnostic and Prognostic Role","AIRWAY-VDAP","INCLUSION CRITERIA:\n\n* Children with bronchiolitis \\\u003C24 months of age clinically characterized according to the clinical definition accepted by international literature (Ralstone);\n* Children with asthma according to most recent GINA guidance (Global Initiative for Asthma, 2022) aged 6-12 years in a phase of proper control or during acute exacerbations;\n* Adults with upper aerodigestive tract chronic or acute clinical conditions;\n* Adults with pathologic diagnosis of head and neck cancer addressed to radiotherapy with or without chemotherapy for primary treatment of the tumor.\n\nEXCLUSION CRITERIA:\n\n* Children with comorbidities including genetic disorders;\n* Children with other chronic respiratory conditions (bronchodysplasia, cystic fibrosis);\n* Children with primary immunologic diseases;\n* Children with prematurity;\n* Children with other respiratory conditions not part of the inclusion criteria (examples: pneumonia, tonsillitis);\n* Adults over 70 years old or with neurological diseases;\n* Adults with syndromic disease;\n* Adults with malformations of upper aero-digestive tract;\n* Adults with history of head and neck surgery or not able to sustain a vocalism for more than 3 sec.","70 Years",{"count":597,"type":22},200,[69],"Acute and Chronic respiratory conditions represent a leading cause of death and morbidity in children and adults worldwide. The diagnosis of bronchiolitis and asthmatic exacerbations is based on clinical, and mostly subjective, clinical parameters with moderately accurate prognostic role. Patients undergoing neck radiotherapy need invasive assessments of larynx. A simple biomarker like Voice may facilitate the management of these conditions. Recent studies showed that VOICE may be used as a good and easy biomarker to diagnose and monitor several respiratory and non-respiratory conditions. A prospective study aimed to collected VOICE and other clinical data in adults and children with common acute and chronic respiratory conditions at high impact on healthcare systems will be performed. VOICE-omic data will be linked with clinical findings generating data integration, using artificial intelligence technology to develop a Decision Support Systems to provide the basis for non-invasive personalised early recognition, diagnosis, monitoring and prognosis of patients with these conditions.",[601,602,603,31,604],"Airway Disease","Cancer of Head and Neck","Radiotherapy","Asthma","2024-10-17",{"date":607,"type":38},"2024-10-18",{"date":609,"type":22},"2024-11-30",{"date":611,"type":22},"2026-09-01",{"name":613,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":17,"minAge":147,"maxAge":622,"enrollmentInfo":623,"targetDuration":625,"studyType":125,"phases":4,"briefSummary":626,"conditions":627,"keywords":633,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":640,"startDateStruct":642,"completionDateStruct":644,"leadSponsor":646,"locationsCount":114},"100398696","pediatric-and-ambulatory-research-in-infectious-diseases-100398696","NCT04471493","Pediatric and Ambulatory Research in Infectious Diseases","Real Time Surveillance of Pediatric Infectious Diseases in French Ambulatory Care: PARI Study","PARI","Inclusion Criteria:\n\n* Children under 16 years of age with at least one infectious disease among:\n* pharyngitis\n* otitis\n* pneumonia\n* influenza\n* bronchiolitisz\n* varicella\n* gastroenteritis\n* enterovirus disease\n* bordetella pertussis disease\n* using the same same software, Axi5-Infansoft (developed by CompuGroup Medical, Nanterre, France)\n\nExclusion Criteria:\n\n* parental refusal","16 Years",{"count":624,"type":22},400000,"5 Years","Many ambulatory networks are mainly based on diagnoses made by first-line physicians not specifically trained to join the network. Here we aim to set up a surveillance network on pediatric infectious diseases with an investment in teaching with specific trainings of participating pediatricians, increasing in use of point of care tests, and automated data extraction from the computers of the pediatricians.",[628,31,629,630,631,28,632],"Otitis","Influenza","Pharyngitis","Varicella","Gastroenteritis",[634,635,636,637,638],"Vaccination","Antibiotic treatment","Point of care test","automated data extraction","network","2024-02-07",{"date":641,"type":38},"2024-02-08",{"date":643,"type":38},"2017-06-26",{"date":645,"type":22},"2030-08-02",{"name":208,"class":45},{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":653,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":144,"enrollmentInfo":655,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":657,"conditions":658,"keywords":665,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":668,"lastUpdatePostDateStruct":669,"startDateStruct":671,"completionDateStruct":673,"leadSponsor":675,"locationsCount":676},"100525619","outcomes-of-children-after-hospitalization-in-intensive-care-unit-100525619","NCT06124092","Outcomes of Children After Hospitalization in Intensive Care Unit","After Pediatric Critical Illness (APCI)","APCI","Inclusion Criteria:\n\n* Children ≤18yo hospitalized in PICU for ≥96 hours\n\nExclusion Criteria:\n\n1. gestational age \\\u003C37 weeks or age \\>18 years at PICU entry;\n2. admitted for congenital heart surgery (followed in neuro-cardiac clinics in most centers);\n3. anticipated life expectancy \\\u003C1year (e.g., active do not resuscitate status).",{"count":656,"type":22},690,"More than 10,000 children are hospitalized in an PICU every year in Canada. While most of them will survive their PICU hospitalization and their critical illness, some children will not recover to their pre-illness level. Some may develop behavioral, physical, emotional or developmental problems and difficulties at school. All these problems are elements that are part of the Pediatric Post-Intensive Care Syndrome (PICS-p).\n\nIt is important to understand the elements (risk factors) that play a role in the development of PICS-p. In Canada, there is no systematic follow-up for children after they leave the PICU. Understanding what can cause PICS-p (risk factors) and how much PICS-p has an impact on children and their family is very important to the family well-being.",[659,660,661,662,663,664,28,31],"Renal Disease","Liver Diseases","Heart Diseases","Trauma Injury","Sepsis","Septic Shock",[666,667],"Pediatric Intensive Care Unit","PICU","2023-11-03",{"date":670,"type":38},"2023-11-09",{"date":672,"type":22},"2024-03",{"date":674,"type":22},"2029-03",{"name":353,"class":45},8]